Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Want to see COYA full AI Analyst Report?
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.50
▼(-5.86% Downside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by heavy losses and ongoing cash burn despite conservative leverage. Technicals are moderately supportive with improving short-term trend and positive MACD, but overbought signals temper the setup. Valuation is constrained by negative earnings, while recent regulatory and program milestones provide a meaningful positive offset.
Positive Factors
Regulatory Progress & Trial Expansion
Fast Track designation and IND acceptance materially improve regulatory pathway durability and de-risk timelines for COYA 302. Broadened enrollment criteria enhance trial recruitment feasibility and the probability of timely, informative Phase 2 readouts that matter for long-term development and partnering prospects.
Negative Factors
Persistent Cash Burn
Continued negative operating and free cash flow mean the company remains reliant on external capital to sustain R&D and trials. Over months this raises execution risk if capital markets tighten, increases dilution probability, and limits nimbleness in extending programs or responding to setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress & Trial Expansion
Fast Track designation and IND acceptance materially improve regulatory pathway durability and de-risk timelines for COYA 302. Broadened enrollment criteria enhance trial recruitment feasibility and the probability of timely, informative Phase 2 readouts that matter for long-term development and partnering prospects.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$103.68M
Dividend YieldN/A
Average Volume (3M)266.35K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth115.44%
EPS Growth-1.14%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap-488.39
Enterprise Value/Revenue-6.38K
Enterprise Value/Gross Profit-6.39K
Enterprise Value/Ebitda2.32K
Forecast
1Y Price Target
$15.40Price Target Upside222.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$2.71M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as T...
How the Company Makes Money
null...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.94M | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 7.92M | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -21.85M | -20.24M | -17.20M | -7.33M | -9.26M | -4.85M |
| Net Income | -21.13M | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | ||||||
| Total Assets | 53.27M | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 50.72M | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 4.30M | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 48.97M | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | ||||||
| Free Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -2.05M | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 31.36M | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Negative
4.78
Price Trends
4.44
Negative
4.55
Negative
5.28
Negative
Market Momentum
0.07
Positive
45.04
Neutral
32.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Negative. The current price of 4.78 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 4.44, and below the 200-day MA of 5.28, indicating a bearish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 45.04 is Neutral, neither overbought nor oversold. The STOCH value of 32.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $179.58M | -1.87 | -30.90% | ― | ― | 10.70% | |
53 Neutral | $163.28M | 10.60 | 35.58% | ― | 93.50% | ― | |
52 Neutral | $103.68M | -3.50 | -0.17% | ― | 115.44% | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $88.03M | -8.71 | -666.47% | ― | -100.00% | 46.40% | |
46 Neutral | $351.20M | -10.31 | -60.73% | ― | -78.29% | 54.16% | |
42 Neutral | $65.48M | -1.29 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
4.42
-1.46
-24.83%
INO
Inovio Pharmaceuticals
1.07
-1.15
-51.80%
SPRO
Spero Therapeutics
2.82
0.06
2.17%
ANVS
Annovis Bio
1.89
-1.17
-38.24%
NKTX
Nkarta
2.51
0.64
34.22%
STTK
Shattuck Labs
4.58
3.39
284.87%
Coya Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Coya Therapeutics Establishes $30 Million ATM Equity Program
Neutral
May 12, 2026
On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to offer and sell up to $30 million of its common stock through at-the-market offerings on the Nasdaq Capital Market. The sha...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
Positive
May 12, 2026
On May 12, 2026, Coya Therapeutics reported first-quarter 2026 results and a corporate update, highlighting U.S. FDA Fast Track Designation granted on March 11, 2026 for its ALS candidate COYA 302 and FDA acceptance of an IND for COYA 302 in front...
Business Operations and StrategyExecutive/Board Changes
Coya Therapeutics Announces Leadership Changes and New Director
Neutral
Apr 2, 2026
Coya Therapeutics, Inc. is a Houston-based, clinical-stage biotechnology company focused on developing proprietary treatments that leverage regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.